In February 2021 Medical Devices industry venture financing deals total $811.82m in the US

Total medical devices industry venture financing deals worth $811.82m were announced in the US in February 2021, led by $105m venture financing of Truvian Sciences, according to GlobalData’s deals database.

The value marked a decrease of 28.8% over the previous month of $1.14bn and a drop of 4.6% when compared with the last 12-month average of $851.05m.

The US held a 66.54% share of the global medical devices industry venture financing deal value that totaled $1.22bn in February 2021.

In terms of venture financing deal activity, the US recorded 40 deals during February 2021, marking a decrease of 20.00% over the previous month and a drop of 27.27% over the 12-month average.

The top five medical devices industry venture financing deals accounted for 52.5% of the overall value during February 2021.

The combined value of the top five medical devices ventures financing deals stood at $426m, against the overall value of $811.82m recorded for the month.

List of Top Medical Devices Industry Financial Deals

The top five medical devices industry venture financing deals of February 2021 tracked by GlobalData were:

1) GreatPoint Ventures, TYH Ventures, Wasson Enterprise, DNS Capital, General Catalyst Partners, Glen Tullman,  and Wittington Ventures’ $105m venture financing of Truvian Sciences

2) The $103m venture financing of Personal Genome Diagnostics by Rock Springs Capital Management, Sands Capital Management, Vensana Capital, Catalio Capital Management, Cowen Healthcare Investments, Innovatus Capital Partners, Kern Capital Management, New Enterprise Associates, Northpond Ventures, PFM Health Sciences,  and Windham Venture Partners

3) Axiom Associates, Altium Capital,  GV Management Co, Colle Capital Partners,  Huamin Investment Management, and Nextrans’ $90m venture financing of Hyperfine Research

4) The $68m venture financing of Syapse by Ally Bridge Group and Northpond Ventures

5) Duquesne Family Office, Schusterman Family Investments, TLV Partners, Catalio Capital Management, Dexcel Pharma,  and Viola Ventures’ venture financing of Immunai for $60m.

Source: GlobalData

Leave a Reply

Your email address will not be published. Required fields are marked *